Table 2.
Association of Cytomegalovirus Immunoglobulin G with Sociodemographic and Clinical Variables by HIV-1 Status
| HIV uninfected (n = 54) | HIV-1 infected aviremic (n = 58) | HIV-1 infected viremic (n = 52) | ||||
|---|---|---|---|---|---|---|
| ρa | p-value | ρa | p-value | ρa | p-value | |
| Continuous variables | ||||||
| Age, years | 0.41 | 0.002 | 0.20 | 0.138 | 0.34 | 0.014 |
| CESD | −0.22 | 0.107 | 0.11 | 0.430 | −0.08 | 0.601 |
| BMI | 0.18 | 0.196 | 0.03 | 0.810 | −0.18 | 0.234 |
| eGFR | −0.29 | 0.033 | 0.002 | 0.989 | −0.48 | <0.001 |
| CD4+ T cell count (cells/mm3) | 0.18 | 0.204 | −0.22 | 0.101 | −0.24 | 0.088 |
| CD8+ T cell count (cells/mm3) | 0.12 | 0.396 | 0.12 | 0.382 | −0.15 | 0.300 |
| CD4/CD8 ratio | 0.02 | 0.898 | −0.30 | 0.022 | −0.15 | 0.295 |
| log10 HIV-1 RNA in plasma | NA | NA | NA | NA | 0.13 | 0.360 |
| log10 HIV-1 RNA in CVL | NA | NA | NA | NA | 0.09 | 0.516 |
| HIV uninfected (n = 54) | HIV-1 infected aviremic (n = 58) | HIV-1 infected viremic (n = 52) | ||||
|---|---|---|---|---|---|---|
| Median (IQR) | p-valueb | Median (IQR) | p-valueb | Median (IQR) | p-valueb | |
| Categorical variablesc | ||||||
| Race/ethnicity | ||||||
| African American/black | 34.3 (22.7–39.8) | 0.030 | 34.9 (22.2–40.2) | 0.508 | 38.2 (31.9–45.0) | 0.656 |
| Hispanic | 16.7 (9.4–23.1) | 28.8 (22.7–33.5) | 35.1 (24.3–39.6) | |||
| White/other | 66.8 (23.5–110.2) | 25.0 (16.6–65.2) | 39.2 (38.4–42.5) | |||
| Current smoker | ||||||
| Yes | 32.3 (22.6–35.7) | 0.311 | 37.3 (26.5–40.2) | 0.209 | 40.0 (33.0–45.0) | 0.029 |
| No | 35.4 (16.7–42.3) | 30.1 (21.0–39.3) | 35.5 (26.2–39.2) | |||
| Diabetes everd | ||||||
| Yes | 34.0 (18.3–41.0) | 0.884 | 34.2 (20.4–41.8) | 0.852 | 38.4 (28.4–40.3) | 0.609 |
| No | 32.9 (21.2–39.5) | 31.1 (22.7–39.9) | 38.7 (32.1–45.0) | |||
| Hypertension (current)e | ||||||
| Yes | 35.7 (32.3–41.5) | 0.015 | 37.5 (21.7–42.9) | 0.081 | 42.6 (32.2–90.7) | 0.046 |
| No | 25.6 (13.4–35.9) | 30.9 (20.3–37.1) | 36.3 (30.1–39.6) | |||
| HCV positive | ||||||
| Yes | 32.84 (29.00–35.69) | 0.900 | 38.86 (30.85–41.27) | 0.151 | 41.99 (39.39–45.67) | 0.033 |
| No | 34.04 (16.71–40.03) | 30.53 (21.42–38.44) | 35.96 (26.17–42.99) | |||
| HIV-1 VL in CVL | ||||||
| >40 copies/ml | NA | NA | NA | NA | 38.8 (34.8–43.3) | 0.655 |
| <40 copies/ml | NA | NA | 38.2 (33.0–40.0) | |||
| Negative | NA | NA | 37.6 (26.0–43.6) | |||
a
Spearman rank correlation coefficient.
b
p-values by Wilcoxan rank-sum test.
c
Current employment, annual income, and education were not significant in any of the subgroups and are not shown in the table.
d
Every self-reported antidiabetic medication or any fasting glucose ≥126 or hemoglobin A1c ≥6.5% or self-reported diabetes is confirmed.
e
Any indication of hypertension (SBP ≥140, DBP ≥90, self-report, or use of antihypertensive medications) at visit.